EyePoint Pharmaceuticals
 | This article needs additional citations for verification. (March 2020) |
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (November 2024) |
| Formerly | pSivida Corp. |
|---|---|
| Company type | Public company |
| Nasdaq: EYPT ASX: PVA FWB: PV3 | |
| Industry | Pharmaceuticals |
| Headquarters | , |
Number of locations | 2 |
| Products | Iluvien |
| Website | www |
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).[citation needed] QinetiQ continues to be a strategic partner.[1][2]
In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4] Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.[5]
See also
[edit]- Alimera Sciences, pSvida's partner on Iluvien
References
[edit]- ^ a b "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
- ^ "Nano silicon boosts tumour fight". 2004-06-18. Retrieved 2020-10-29.
- ^ "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
- ^ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.
- ^ "pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc". EyePoint Pharmaceuticals. March 28, 2018. Retrieved March 28, 2018.
External links
[edit]- Official website
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
- Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015.
pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon"
- pSivida Mesoporous silicon patent
| Divisions and subsidiaries |
| ||||
|---|---|---|---|---|---|
| Shareholdings and partnerships | |||||
| Products | |||||
| Places and vessels | |||||
| Predecessors | |||||
| People | |||||
 | This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |